Home Cart Sign in  
Chemical Structure| 112559-91-8 Chemical Structure| 112559-91-8

Structure of Hydroxy Itraconazole
CAS No.: 112559-91-8

Chemical Structure| 112559-91-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hydroxy itraconazole is an active metabolite of Itraconazole (ITZ), which is a triazole antifungal agent.

Synonyms: Itraconazole metabolite Hydroxy Itraconazole; R-63373; hydroxy-ITZ

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hydroxy Itraconazole

CAS No. :112559-91-8
Formula : C35H38Cl2N8O5
M.W : 721.63
SMILES Code : O=C1N(C(C)C(O)C)N=CN1C2=CC=C(N3CCN(C4=CC=C(OCC5OC(CN6N=CN=C6)(C7=CC=C(Cl)C=C7Cl)OC5)C=C4)CC3)C=C2
Synonyms :
Itraconazole metabolite Hydroxy Itraconazole; R-63373; hydroxy-ITZ
MDL No. :MFCD28964104

Safety of Hydroxy Itraconazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02633709 Spinal Muscular Atrophy Phase 1 Completed - Netherlands ... More >> Pra International Group B.V Groningen, Netherlands, 9728 NZ Less <<
NCT02093728 Solid Tumours Phase 1 Completed - United States, Kansas ... More >> Research Site Overland Park, Kansas, United States Less <<
NCT02157883 Advanced Non Small Cell Lung C... More >>ancer Advanced (Inoperable) Non Small Cell Lung Cancer Less << Phase 1 Active, not recruiting December 31, 2018 United States, California ... More >> Research Site San Diego, California, United States, 92123 United States, Ohio Research Site Cleveland, Ohio, United States, 44106-4950 Belgium Research Site Edegem, Belgium, 2650 Research Site Gent, Belgium, 9000 Korea, Republic of Research Site Seongnam-si, Korea, Republic of, 13620 Research Site Seoul, Korea, Republic of, 03080 Research Site Seoul, Korea, Republic of, 03722 Research Site Seoul, Korea, Republic of, 06351 Research Site Seoul, Korea, Republic of, 138-736 Netherlands Research Site Amsterdam, Netherlands, 1066 CX Research Site Maastricht, Netherlands, 6229 HX Research Site Rotterdam, Netherlands, 3015 CE Taiwan Research Site Taipei, Taiwan, 10002 Research Site Taipei, Taiwan, 11217 United Kingdom Research Site London, United Kingdom, SE1 9RT Research Site Manchester, United Kingdom, M20 4BX Less <<
NCT02653872 - Completed - -
NCT02370615 Japanese Healthy Adult Males Phase 1 Completed - Japan ... More >> Osaka-shi, Osaka, Japan Less <<
NCT03209648 Healthy Participants Phase 1 Completed - United Kingdom ... More >> Covance Clinical Research Unit Ltd. Leeds, United Kingdom, LS2 9LH Less <<
NCT01913379 Healthy Subjects ... More >> Pharmacokinetics Drug-Drug Interaction Less << Phase 1 Completed - France ... More >> SGS Paris, France, 75015 Less <<
NCT02653872 Healthy Subjects Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT02259010 Advanced Solid Tumors ... More >> Relapsed/Refractory Lymphoma Less << Phase 1 Unknown April 2016 United States, Missouri ... More >> St. Louis, Missouri, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, Tennessee Germantown, Tennessee, United States United States, Texas Dallas, Texas, United States Less <<
NCT02370615 - Completed - -
NCT03624959 Healthy Volunteer Phase 1 Recruiting April 15, 2019 United States, Texas ... More >> PPD Phase 1 Clinic Recruiting Austin, Texas, United States, 78744 Less <<
NCT02157883 - Active, not recruiting - -
NCT02122692 Healthy Volunteers Phase 1 Completed - France ... More >> FR801 Rennes, France, 35042 Less <<
NCT02175407 Pharmacokinetics ... More >> DDI (Drug-Drug Interaction) Healthy Subjects Less << Phase 1 Completed - Germany ... More >> PAREXEL International GmbH Berlin, Germany, 14050 Less <<
NCT02328443 Healthy Phase 1 Completed - -
NCT02838264 Healthy Phase 1 Completed - Belgium ... More >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 Less <<
NCT02706535 Drug Interactions Phase 1 Completed - United States, Maryland ... More >> GSK Investigational Site Baltimore, Maryland, United States, 21225 Less <<
NCT03579719 Healthy Volunteers Phase 1 Recruiting November 10, 2018 Netherlands ... More >> Pra International Group B.V Recruiting Groningen, Netherlands, 9728 NZ Less <<
NCT02975037 Healthy Phase 4 Unknown April 2017 -
NCT02698267 Neuropathic Pain Phase 1 Completed - United Kingdom ... More >> Research Site Leeds, United Kingdom, LS2 9LH Less <<
NCT02513446 Healthy Phase 1 Completed - Germany ... More >> 1320.20.1 Boehringer Ingelheim Investigational Site Biberach, Germany Less <<
NCT02085967 Healthy Subjects Phase 1 Completed - United States, Texas ... More >> PPD Development LLC Austin, Texas, United States, 78744 Less <<
NCT02055703 Healthy Subjects Phase 1 Completed - United States, Texas ... More >> WCT Early Development San Antonio, Texas, United States, 78217 Less <<
NCT01787331 - Completed - -
NCT02230033 Healthy Phase 1 Completed - United States, Arizona ... More >> Tempe, Arizona, United States Less <<
NCT03222310 Healthy Volunteers Phase 1 Completed - United States, Texas ... More >> Covance Research Unit - Dallas Dallas, Texas, United States, 75247 Less <<
NCT02831972 Healthy Phase 1 Completed - United States, Arizona ... More >> Tempe, Arizona, United States, 85283 Less <<
NCT01214941 Pharmacokinetics ... More >> Pharmacodynamics Less << Phase 4 Completed - Finland ... More >> Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital Turku, Finland, 20521 Less <<
NCT01929876 Healthy Participants Phase 1 Completed - United States, Texas ... More >> Dallas, Texas, United States, 75247 Less <<
NCT01409018 Pediatric, Cancer Phase 1 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Chongno-gu, Korea, Republic of Less <<
NCT03259542 Drug Interaction Potentiation ... More >> Healthy Less << Phase 1 Completed - United States, Florida ... More >> SeaView Research Miami, Florida, United States, 33126 Less <<
NCT02130661 Alzheimer's Disease Phase 1 Withdrawn January 2018 -
NCT01787331 Prostate Adenocarcinoma ... More >> Recurrent Prostate Carcinoma Stage I Prostate Adenocarcinoma AJCC v7 Stage II Prostate Adenocarcinoma AJCC v7 Stage III Prostate Adenocarcinoma AJCC v7 Less << Phase 2 Completed - United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94115 Less <<
NCT01929876 - Completed - -
NCT03512548 Healthy Phase 1 Recruiting December 31, 2018 United States, Arizona ... More >> Celerion Recruiting Tempe, Arizona, United States, 85283 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.39mL

0.28mL

0.14mL

6.93mL

1.39mL

0.69mL

13.86mL

2.77mL

1.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories